SEARCH:   Advanced

Blood, 1 June 2008, Vol. 111, No. 11, pp. 5371-5379. Prepublished online as a Blood First Edition Paper on March 31, 2008; DOI 10.1182/blood-2007-11-124958. This Article Full Text (PDF) Supplemental Methods, Appendix, Tables, and Figures All Versions of this Article: blood-2007-11-124958v1 111/11/5371    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Langer, C. Articles by Bloomfield, C. D. Search for Related Content PubMed PubMed Citation Articles by Langer, C. Articles by Bloomfield, C. D. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 27, 2007 Accepted March 18, 2008 High BAALC expression associates with other molecular prognostic markers, poor outcome and a distinct gene-expression signature in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study Christian Langer, Michael D. Radmacher, Amy S. Ruppert, Susan P. Whitman, Peter Paschka, Krzysztof Mrozek, Claudia D. Baldus, Tamara Vukosavljevic, Chang-Gong Liu, Mary E. Ross, Bayard L. Powell, Albert de la Chapelle, Jonathan E. Kolitz, Richard A. Larson, Guido Marcucci, and Clara D. Bloomfield* Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States The Cancer and Leukemia Group B (CALGB) Statistical Center, Duke University Medical Center, Durham, NC, United States Department of Hematology and Oncology, Charite University Hospital, Campus Benjamin Franklin, Berlin, Germany Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States Center for Childhood Cancer, The Research Institute at Nationwide Children's Hospital, Columbus, OH, United States Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, United States Department of Medicine, North Shore University Hospital, Manhasset, NY, United States Department of Medicine, University of Chicago, Chicago, IL, United States * Corresponding author; email: clara.bloomfield{at}osumc.edu. BAALC expression is regarded as an independent prognostic factor in cytogenetically normal acute myeloid leukemia (CN-AML), but has hitherto not been investigated together with multiple other established prognostic molecular markers in CN-AML. We analyzed BAALC expression in 172 primary CN-AML patients aged <60 years, treated similarly on CALGB protocols, and found that high BAALC expression was associated with FLT3-ITD (P=.04), wild-type NPM1 (P<.001), mutated CEBPA (P=.003), MLL-PTD (P=.009), absent FLT3-TKD (P=.005) and high ERG expression (P=.05). In multivariable analysis, high BAALC expression independently predicted lower complete remission rates (P=.04) when adjusting for ERG expression and age, and shorter survival (P=.04) when adjusting for FLT3-ITD, NPM1, CEBPA and white blood count. A gene-expression signature of 312 probe sets differentiating high from low BAALC expressers was identified. High BAALC expression was associated with overexpression of genes involved in drug resistance (MDR1) and stem-cell markers (CD133, CD34, KIT). Global microRNA-expression analysis did not reveal significant differences between BAALC expression groups. However, an analysis focused on microRNAs that putatively target BAALC revealed a potentially interesting inverse association between expression of miR-148a and BAALC. We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene expression profile. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K. H. Metzeler, A. Dufour, T. Benthaus, M. Hummel, M.-C. Sauerland, A. Heinecke, W. E. Berdel, T. Buchner, B. Wormann, U. Mansmann, et al. ERG Expression Is an Independent Prognostic Factor and Allows Refined Risk Stratification in Cytogenetically Normal Acute Myeloid Leukemia: A Comprehensive Analysis of ERG, MN1, and BAALC Transcript Levels Using Oligonucleotide Microarrays J. Clin. Oncol., October 20, 2009; 27(30): 5031 - 5038. [Abstract] [Full Text] [PDF] C. G. Mullighan Mutations of NOTCH1, FBXW7, and prognosis in T-lineage acute lymphoblastic leukemia Haematologica, October 1, 2009; 94(10): 1338 - 1340. [Full Text] [PDF] R. Tang, P. Hirsch, F. Fava, S. Lapusan, C. Marzac, I. Teyssandier, J. Pardo, J.-P. Marie, and O. Legrand High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukemia Blood, October 1, 2009; 114(14): 2993 - 3000. [Abstract] [Full Text] [PDF] E. R. Mardis, L. Ding, D. J. Dooling, D. E. Larson, M. D. McLellan, K. Chen, D. C. Koboldt, R. S. Fulton, K. D. Delehaunty, S. D. McGrath, et al. Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome N. Engl. J. Med., September 10, 2009; 361(11): 1058 - 1066. [Abstract] [Full Text] [PDF] C. Langer, G. Marcucci, K. B. Holland, M. D. Radmacher, K. Maharry, P. Paschka, S. P. Whitman, K. Mrozek, C. D. Baldus, R. Vij, et al. Prognostic Importance of MN1 Transcript Levels, and Biologic Insights From MN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study J. Clin. Oncol., July 1, 2009; 27(19): 3198 - 3204. [Abstract] [Full Text] [PDF] U. Bacher, A. Kohlmann, and T. Haferlach Perspectives of gene expression profiling for diagnosis and therapy in haematological malignancies Brief Funct Genomic Proteomic, May 27, 2009; (2009) elp011v1. [Abstract] [Full Text] [PDF] M. Pigazzi, E. Manara, E. Baron, and G. Basso miR-34b Targets Cyclic AMP-Responsive Element Binding Protein in Acute Myeloid Leukemia Cancer Res., March 15, 2009; 69(6): 2471 - 2478. [Abstract] [Full Text] [PDF] G. Marcucci, K. Maharry, M. D. Radmacher, K. Mrozek, T. Vukosavljevic, P. Paschka, S. P. Whitman, C. Langer, C. D. Baldus, C.-G. Liu, et al. Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study J. Clin. Oncol., November 1, 2008; 26(31): 5078 - 5087. [Abstract] [Full Text] [PDF] T. Buchner, W. E. Berdel, J. Kienast, A. Quintas-Cardama, W. Saber, E. C. Williams, H. Narimatsu, R. Schlenk, K. Dohner, and H. Dohner Cytogenetically normal acute myeloid leukemia. N. Engl. J. Med., August 7, 2008; 359(6): 651 - 652. [Full Text] [PDF] B. Lowenberg Acute Myeloid Leukemia: The Challenge of Capturing Disease Variety Hematology, January 1, 2008; 2008(1): 1 - 11. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020